Getting ready to sign a partner in Europe for Dynepo (epoetin delta), its version of erythropoietin, Transkaryotic Therapies Inc. had been bracing an eager market for data from the pivotal Phase III trial with another therapy - iduronate-2-sulfatase for Hunter syndrome, expected in the second half of 2005, with Phase I/II data due about the same time from the open-label Phase I/II trial testing of yet another enzyme-replacement therapy, GA-GCB in Gaucher's disease.
In what could be the largest acquisition of 2005 - and certainly the largest so far - Shire Pharmaceuticals Group plc has nabbed Transkaryotic Therapies Inc. in a deal worth $1.6 billion. (BioWorld Today)
RSS